Close menu




VALNEVA SE EO -_15

Photo credits: pixabay.com

Commented by Mario Hose on January 20th, 2022 | 11:08 CET

Cardiol, Novavax, Valneva - Why it's worth buying now!

  • Investments

The trading week is coming to an end and on Thursday the German benchmark index DAX continues to trade below the psychological mark of 16,000 points at a level of 15,785 points and an increase of 0.10%. The rest of today and Friday remain to make a jump. It will probably depend on the guidance from the U.S., but at the hour, U.S. futures are all green. MDAX last traded at 34,135 points (+0.07%), TecDAX at 3,544 points (+0.07%) and SDAX at 15,626 points up 0.33%. Companies from the biotech sector are again in the focus of the investors today.

Read

Commented by Stefan Feulner on January 20th, 2022 | 09:15 CET

Valneva, XPhyto, BioNTech - This is the breakthrough

  • Biotechnology

The shares of vaccine manufacturers are currently experiencing a rollercoaster ride. While BioNTech, Pfizer and Moderna vaccines, based on mRNA technology, continue to reduce their incredible stock market valuation, Valneva, the manufacturer of an inactivated vaccine, has made a brilliant comeback on the stock market floor. The reasons for the good mood were positive data regarding the neutralization of the Omicron variant, which pushed the share up by more than 30% after trading hours.

Read

Commented by Mario Hose on January 14th, 2022 | 12:17 CET

Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus

  • Covid-19

At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.

Read

Commented by Mario Hose on January 13th, 2022 | 18:11 CET

New research results for Covid-19: BioNTech, Cardiol, Valneva

  • Covid-19

In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.

Read

Commented by André Will-Laudien on January 12th, 2022 | 11:03 CET

Valneva, Cardiol Therapeutics, Novavax: Hitting the nail on the head!

  • Biotechnology

What is the correlation between the development of drugs or vaccines and the price of the company in question on the stock market? Difficult to answer because there is an almost infinite number of research areas in the field of biotechnology. Not all of them are at the center of media interest, while some topics, in contrast, experience true hype phases. COVID-19 is a viral disease that is to be overcome with all available research resources, and the attention on the capital markets is correspondingly high. Those who can demonstrate success in this area achieve high prices and valuations. But who will deliver the ultimate vaccine or a revolutionary drug to treat infected people? Lots of speculation, risks and opportunities in equal measure. We take a look at some interesting companies.

Read

Commented by André Will-Laudien on January 10th, 2022 | 10:22 CET

Tembo Gold, BioNTech, Valneva, MorphoSys - Turnaround or crash?

  • Gold

At the beginning of the year, there is much talk about the seemingly eternally running stock markets and the infinite wealth of those who have done everything right. Of course, shorting Tesla was a risk; it went wrong 85% of the time. However, since the "minutes" of the Federal Reserve, it is perhaps not a new short with the announcement. Because interest rates will probably have to rise once the tapering gets going. Incidentally, opinions are divided on the inflation trend: some banks estimate a 1 before the decimal point, others see a 5. So what now? Interest rates up mean problems for growth stocks; interest rates down could mean a continuation of the bull market. We take a look at interesting shares with their own stories.

Read

Commented by Nico Popp on January 7th, 2022 | 12:51 CET

BioNTech, XPhyto, Valneva: 3 stocks for next week?

  • Biotechnology

Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.

Read

Commented by André Will-Laudien on December 28th, 2021 | 07:15 CET

BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming

  • Biotechnology

The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.

Read

Commented by Fabian Lorenz on December 23rd, 2021 | 10:31 CET

+900% with Nvidia still not enough? Are Valneva and BrainChip on the verge of a breakthrough?

  • Technology

2021 was not a good year overall for technology and growth stocks. In particular, companies with a business model not yet profitable had a hard time. They included Peloton and Zoom. One of the top performers in the Nasdaq-100 was the Nvidia share. The chip giant benefits from several trends at once, such as artificial intelligence and the metaverse. If UBS has its way, then 900% price gains in the past three years are not enough. For the analysts of the Swiss bank, the chip stock is the "Top Pick 2022". BrainChip is still a long way from the chip Olympus, but the Company could make a breakthrough in the coming year. The same applies to Valneva, as many are waiting for the dead vaccine, and the stock is still valued relatively low.

Read

Commented by André Will-Laudien on December 21st, 2021 | 13:54 CET

Troilus Gold, Valneva, Moderna, BioNTech - Where will these stocks be in 2022?

  • Gold

The winners in the 2021 investment year have undeniably been the hydrogen, lithium and vaccine stocks. They temporarily gained up to 2,000% but also corrected by more than 50% in some cases. These value developments were not always fundamentally justified. Often the assumption of future achievements was sufficient for a corresponding positive development. In the case of the vaccine manufacturers, the stock market players' fantasies were fulfilled; in the case of hydrogen, this statement was valid at least for a 3-month window at the beginning of the year. Unfortunately, the year was disappointing for most gold explorers, as the precious yellow metal was unable to capitalize on the great uncertainty since the outbreak of the pandemic with a price increase. But this could change in 2022 ad hoc!

Read